Summary Two children affected by severe aplastic anaemia (SAA) underwent allogeneic bone marrow transplantation (BMT) using partially matched family donors. In both cases there was a successful engraftment of donor haemopoietic stem cells. However, after an initial erythropoietic recovery, 5 months following BMT both children became severely anaemic. Although multiple factors were responsible for anaemia, in both cases there was a markedly impaired erythropoietin response to anaemia, as indicated by the inappropriately low levels of serum erythropoietin (EPO). Treatment with recombinant human erythropoietin (rHuEPO) induced a sustained erythropoietic response with complete correction of anaemia. This pilot study suggests that rHuEPO can be effective in correcting long‐lasting anaemia after marrow transplantation, characterized by inadequate erythropoietin production. Copyright © 1992, Wiley Blackwell. All rights reserved
Recombinant human erythropoietin is effective in correcting erythropoietin‐deficient anaemia after allogeneic bone marrow transplantation / Locatelli, F.; Pedrazzoli, P.; Barosi, G.; Zecca, M.; Porta, F.; Liberato, L.; Gambarana, D.; Nespoli, L.; Cazzola, M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 80:4(1992), pp. 545-549. [10.1111/j.1365-2141.1992.tb04571.x]
Recombinant human erythropoietin is effective in correcting erythropoietin‐deficient anaemia after allogeneic bone marrow transplantation
Locatelli F.;
1992
Abstract
Summary Two children affected by severe aplastic anaemia (SAA) underwent allogeneic bone marrow transplantation (BMT) using partially matched family donors. In both cases there was a successful engraftment of donor haemopoietic stem cells. However, after an initial erythropoietic recovery, 5 months following BMT both children became severely anaemic. Although multiple factors were responsible for anaemia, in both cases there was a markedly impaired erythropoietin response to anaemia, as indicated by the inappropriately low levels of serum erythropoietin (EPO). Treatment with recombinant human erythropoietin (rHuEPO) induced a sustained erythropoietic response with complete correction of anaemia. This pilot study suggests that rHuEPO can be effective in correcting long‐lasting anaemia after marrow transplantation, characterized by inadequate erythropoietin production. Copyright © 1992, Wiley Blackwell. All rights reservedI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
